OBJECTIVES:  At the end of 2006, there was an important reform in the Hungarian pharmaceutical market, including serious changes in the health insurance reimbursement of medicines. In 2008, the world economic crisis significantly affected the public expenditures in many countries. The aim of our study is to analyze the changes in the Hungarian health insurance pharmaceutical budget between 2006-2015. METHODS:  Data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP), the only health care financing agency in Hungary. We analyzed the changes of the pharmaceutical budget between 2006-2015. Results are given in Hungarian Forint (HUF) and US dollars (USD). The annual average currency exchange rates were applied according to the data of the Central Bank of Hungary. RESULTS:  In the first year, the Hungarian pharmaceutical budget decreased from 388.7 billion HUF (2006) to 323.6 billion HUF (2007) by 65.1 billion HUF (16.7 %). This decrease was a bit moderate in USD dollar (0.1 billion USD, 4.7 %) due to the stronger Hungarian currency. For 2011, the pharmaceutical budget slightly increased compared to 2007 up to 376.9 billion HUF (1.88 billion USD). The increase was moderate in USD due to the weakening Hungarian currency. Between 2012-2015. the pharma budget remained in the range of 296-326 billion HUF (1.17-1.3 billion USD). CONCLUSIONS:  Due to the reform of the whole Hungarian pharmaceutical market and as the effect of economic crisis, the Hungarian health insurance pharmaceutical budget significantly decreased between 2006-2015. Between 2006-2009 this decline became higher as the Hungarian currency weakened compared USD during the world economic crisis. Between 2012-2015. the pharma budget have been stabilized.